DOCSLIB.ORG

Studies of the Mode of Action of Anthelmintic Drugs: Tools to Investigate the Biochemical Pecularities of Helminths H

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Studies of the Mode of Action of Anthelmintic Drugs: Tools to Investigate the Biochemical Pecularities of Helminths H Ann. Parasitol. Hum. Comp., Key-words: Antimonials. Ascaris. Ascaris suum. ATP. Caeno- 1990, 65, Suppl. I : 99-102. rhabditis elegans. Calcium. Cholinergic receptors. Closantel. DNA. Fasciola hepatica. Fumarate reductase. GABA. Hycanthone. Hyme- nolepis diminuta. Ivermectin. Levamisole. Mebendazole. Micro­ tubule. Mitochondria. Nitrobenzylthioinosine. Oxamniquine. Oxi­ dative phosphorylation. Permease. Phosphofructokinase. Praziquantel. Protofilament. Rafoxanide. Schistosoma. Tubercidin. Tubulin. Mots-clés : Antimonies. Ascaris. ATP. Caenorhabditis elegans. Calcium. Récepteurs cholinergiques. Closantel. ADN. Fasciola hepa­ tica. Fumarate réductase. GABA. Hycanthone. Hymenolepis dimi­ nuta. Ivermectine. Levamisole. Mebendazole. Microtubule. Mito­ chondrie. Nitrobenzylthioinosine. Oxamniquine. Phosphorylation oxydative. Perméase. Phosphofructokinase. Praziquantel. Proto­ filament. Rafoxamide. Schistosoma. Tubercidine. Tubuline. STUDIES OF THE MODE OF ACTION OF ANTHELMINTIC DRUGS: TOOLS TO INVESTIGATE THE BIOCHEMICAL PECULARITIES OF HELMINTHS H. VANDEN BOSSCHE Summary -------------------------------------------------------------------------------_ _ An overview is given of the results from mode of action studies zine, levamisole, ivermectine, salicylanilides, praziquantel, benzi- which improved our knowledge of some biochemical and/or elec- midazolecarbamates, oxamniquine and hycanthome offered tools trophysiological aspects of parasitic helminths. Studies of the mole­ to learn more of the parasites and their hosts. cular mechanism of action of for example, antimonials, pipera- R ésumé : Les études sur les mécanismes d’action des anthelmintiques : instruments pour l’analyse des particularités des helminthes. Un certain nombre d’acquisitions anciennes et nouvelles dans dérivés de l’antimoine, la pipérazine, le lévamisole, l’ivermectine, la connaissance de la biochimie et de T électro-physiologie des hel­ les salicylanilides, le praziquantel, les bezimidazole-carbamates, minthes sont passées en revue à partir des données obtenues lors l’oxamniquine et l’hycanthone, pour l’analyse des particularités des études sur les mécanismes d’action. Cette revue sommaire a des helminthes. permis de souligner l’importance des anthelmintiques tels que les Mode of action studies might tell us how a chemical are of great help in the study of the distribution and role compound interferes with a target in the parasite and of sterols in fungal and protozoan membranes (Bolard, changes the host-parasite interplay. These studies also might 1986; Vanden Bossche, 1990). Azole antifungals triggered highlight differences between the organisms and thus the studies on fungal cytochrome P450 and contributed to improve our knowledge of the biochemical systems in host the identification of new opportunities for prostate and and parasite. Already in 1878, Claude Bernard considered breast cancer therapy (Vanden Bossche et al., 1990). pharmacologically active compounds as « instruments well What do we know on the mode of action of anthelmin­ suited for dissecting one by one the properties of the ele­ tics? Do these studies also provide guidance for future ments of the living organisms ». research? The battery of anti-microbial agents that became avai­ lable opened the way to a better understanding of binding sites and active targets (Gale et al., 1981). Antifungal agents Interference with carbohydrate metabolism such as the polyenes and imidazole and triazole derivatives Investigations using trivalent antimonials, the oldest group of compounds used in antischistosomal therapy, have been of great help in elucidating schistosomal glycolysis. Already Department of Comparative Biochemistry, Janssen Research in the early fifties Ernest Bueding and Tag Mansour showed Foundation, Turnhoutseweg, 30, B 2340 Beerse, Belgium. that the activity of schistosomal phosphofructokinase (PFK) 99 Article available at http://www.parasite-journal.org or http://dx.doi.org/10.1051/parasite/1990651099 H. VANDEN BOSSCHE is inhibited by low concentrations of antimonials (Bueding, It is of interest that piperazine does not act on rat sympa­ 1972). Of great interest is the fact that the reduced glycolytic thetic neurons. rate, resulting from inhibition of PFK, could be reversed A more recently developed nematocide, ivermectin, also by the addition of purified mammalian phosphofructoki- paralyzes nematodes by activating membrane chloride con­ nase. These studies proved that PFK is a key regulatory ductance in neurons of the nerve cord (see Rew and Fet­ enzyme in glycolysis, that the mammalian enzyme is much terer, 1986). This might originate from stimulation of the less sensitive (70-80 times) to the antimonials and that schis­ presynaptic release of GABA. The selectivity might result tosomal PFK might be an excellent target for the develop­ from the inability of ivermectin to reach its target in the ment of new antischistosomal drugs. Flowever, none of host central nerves system. This highlights the importance the currently used modern anthelmintics has PFK as target. of pharmacokinetic studies in both parasite and host. Although levamisole inhibits the fumarate reductase in Levamisole causes a spastic contraction of nematode nematodes at relatively high concentrations only, the results muscle by acting as a potent agonist at acetylcholine recep­ obtained pinpoint the fumarate reductase complex as an­ tors on muscle bag membranes of Ascaris suum. Lewis other possible target for anthelmintics. et al. (1980) showed that levamisole-resistant strains of Cae- Salicylanilides such as, closantel and rafoxanide, are norhabditis elegans lack normal cholinergic receptors. The potent fasciolicides. Their activity has been linked to their latter studies not only suggest that nematodal acetylcho­ capacity to uncouple mitochondrial electron-transport asso­ line receptors are targets for levamisole but also focus atten­ ciated phosphorylation. For example, 12 hours after i.m. tion on the small free-living nematode C. elegans. This treatment of the sheep host with 5 mg closantel/kg body nematode and levamisole have contributed to genetic stu­ weight the ATP content of Fasciola hepatica was decreased dies of the nervous system in nematodes (Lewis et al., 1980). by more than 60 % and the adenylate energy charge was 0.53 instead of the 0.84 found in liver flukes from control Interaction with lipid membranes sheep (Vanden Bossche, 1985a). No effect on the oxida­ tive phosphorylation was found in mitochondria isolated Praziquantel has broad spectrum activity against cestodes from livers of uninfected rats and from hearts of rats, and many trematodes. This pyrazinoisoquinoline deriva­ infected and uninfected, 4 and 16 hours after i.m. injec­ tive also induces next to a rapid muscle contraction, vacuo­ tion with 5 mg closantel per kg (Vanden Bossche et al., lization of the tegument, followed by a pronounced struc­ 1980). Studies with closantel offered examples of possibili­ tural disruption of the parasite’s tegument (for a review ties to learn more about Fasciola hepatica and Schisto­ see Vanden Bossche, 1985a). The molecular mechanism soma mansoni. Indeed, studies to measure the effects of underlaying both the tegumental alterations and muscle closantel on liver mitochondria from rats infected with Fas­ contraction are not well understood. However, from the ciola revealed that the mitochondria from untreated rats mode of action studies we learned that muscle contraction were uncoupled (Vanden Bossche et al., 1983). This uncou­ in Hymenolepis diminuta muscle depends on endogenous pling might be induced by a product(s) excreted by the Ca2+, whereas muscle contraction in schistosomes is liver fluke (Vanden Bossche, 1985b). Treatment of the rats dependent on the influx of external Ca2+. The combined with closantel resulted in a normalization of the mitochon­ use of a theoretical approach and experimental procedures drial activity. These Fasciola-induced alterations of liver (such as IR spectroscopy) (Schepers et al., 1988) established mitochondria might be involved in the pathology of fas- the lipid destabilizing capacity of praziquantel. This capa­ cioliasis. Studies on the effects of closantel on S. mansoni city has been explained in terms of the high praziquantel were suggestive of a role for aerobic metabolism in the interaction and the large area occupied per drug molecule generation of energy required by S. mansoni for motility in the lipid layer. It should be mentioned that praziquantel (Vanden Bossche, 1985b). These findings indicate that does not modify the lipid structure but act as a spacer S. mansoni might derive a considerable part of their energy between lipid molecules. This opens new perspectives in from mitochondrial oxidative phorphorylation instead of the search for anthelmintics. However, it might be diffi­ from glycolysis only. cult to find compounds that insert selectively into parasite membranes. Effects on neuromuscular systems As already mentioned, one of the early morphological results of praziquantel treatment is disruption of the inte­ Piperazine, one of the first effective anthelmintics, ini­ grity of the tegument. The membrane over tubercles on tiated important studies on the neuromuscular system of the S. mansoni male dorsal surface is damaged and an Ascaris (for a review see Martin, 1987). It has been shown increase in parasite-specific antigenicity is observed after that piperazine acts as an agonist at the extrasynaptic GABA in vitro treatment (Harnet and Kusel, 1986). Studies
Load more

Recommended publications
  • Comparative Efficacies of Commercially Available Benzimidazoles Against Pseudodactylogyrus Infestations in Eels
    DISEASES OF AQUATIC ORGANISMS Published October 4 Dis. aquat. Org. l Comparative efficacies of commercially available benzimidazoles against Pseudodactylogyrus infestations in eels ' Department of Fish Diseases, Royal Veterinary and Agricultural University, 13 Biilowsvej, DK-1870 Frederiksberg C, Denmark Department of Pharmacy, Royal Veterinary and Agricultural University, 13 Biilowsvej. DK-1870 Frederiksberg C,Denmark ABSTRACT: The antiparasitic efficacies of 9 benzimidazoles in commercially avalable formulations were tested (water bath treatments) on small pigmented eels Anguilla anguilla, expenmentally infected by 30 to 140 specimens of Pseudodactylogyrus spp. (Monogenea).Exposure time was 24 h and eels were examined 4 to 5 d post treatment. Mebendazole (Vermox; 1 mg 1-') eradicated all parasites, whereas luxabendazole (pure substance) and albendazole (Valbazen) were 100 % effective only at a concen- tration of 10 mg I-'. Flubendazole (Flubenol), fenbendazole (Panacur) and oxibendazole (Lodltac) (10 mg l-') caused a reduction of the infection level to a larger extent than did triclabendazole (Fasinex) and parbendazole (Helmatac).Thiabendazole (Equizole), even at a concentration as high as 100 mg l-', was without effect on Pseudodactylogyrus spp. INTRODUCTION range of commercially available benzimidazole com- pounds. If drug resistance will develop under practical The broad spectrum anthelmintic drug mebendazoIe eel-farm conditions in the future, it is likely to be was reported as an efficacious compound against infes- recognized during treatments with commercially avail- tations of the European eel Anguilla anguilla with gill able drug formulations. Therefore this type of drug parasitic monogeneans of the genus Pseudodactylo- preparations were used in the present study. gyms (Szekely & Molnar 1987, Buchmann & Bjerre- gaard 1989, 1990, Mellergaard 1989).
    [Show full text]
  • Baylisascariasis
    Baylisascariasis Importance Baylisascaris procyonis, an intestinal nematode of raccoons, can cause severe neurological and ocular signs when its larvae migrate in humans, other mammals and birds. Although clinical cases seem to be rare in people, most reported cases have been Last Updated: December 2013 serious and difficult to treat. Severe disease has also been reported in other mammals and birds. Other species of Baylisascaris, particularly B. melis of European badgers and B. columnaris of skunks, can also cause neural and ocular larva migrans in animals, and are potential human pathogens. Etiology Baylisascariasis is caused by intestinal nematodes (family Ascarididae) in the genus Baylisascaris. The three most pathogenic species are Baylisascaris procyonis, B. melis and B. columnaris. The larvae of these three species can cause extensive damage in intermediate/paratenic hosts: they migrate extensively, continue to grow considerably within these hosts, and sometimes invade the CNS or the eye. Their larvae are very similar in appearance, which can make it very difficult to identify the causative agent in some clinical cases. Other species of Baylisascaris including B. transfuga, B. devos, B. schroeder and B. tasmaniensis may also cause larva migrans. In general, the latter organisms are smaller and tend to invade the muscles, intestines and mesentery; however, B. transfuga has been shown to cause ocular and neural larva migrans in some animals. Species Affected Raccoons (Procyon lotor) are usually the definitive hosts for B. procyonis. Other species known to serve as definitive hosts include dogs (which can be both definitive and intermediate hosts) and kinkajous. Coatimundis and ringtails, which are closely related to kinkajous, might also be able to harbor B.
    [Show full text]
  • Mebendazole 1
    The European Agency for the Evaluation of Medicinal Products Veterinary Medicines Evaluation Unit EMEA/MRL/625/99-FINAL July 1999 COMMITTEE FOR VETERINARY MEDICINAL PRODUCTS MEBENDAZOLE SUMMARY REPORT (1) 1. Mebendazole is a benzimidazole anthelmintic which is used in both human and veterinary medicine. In veterinary medicine, it is administered orally to horses, at a target dose of 8.8 mg/kg bw and to sheep and goats at a target dose of 15 mg/kg bw. Mebendazole has also been used in game birds, pigs, deer, poultry and cattle, including lactating animals and laying birds, but these uses were not supported with regard to the establishment of MRLs. Mebendazole is authorised in a range of mono-preparations including premixes for medicated feed, pastes, tablets, liquids, granules, drenches and suspensions for oral administration. Mebendazole is also used in combination products additionally containing either metrifonate, closantel or minerals (selenium, cobalt). 2. The pharmacokinetics of mebendazole was studied in rats, mice, dogs, humans and several target species. In rats given oral doses in the range of 0.06 to 10 mg/kg bw 14C-mebendazole, most of the radioactivity was recovered from the organs of the gastrointestinal tract and consisted mostly of unmetabolised mebendazole. Less than 1% of the administered radioactivity was detected in blood. Excretion was predominantly via the faeces, with 70 to 90% of the faecal radioactivity consisting of unmetabolised mebendazole. In rat liver, 1 hour after administration, 15% of the radioactivity consisted of unmetabolised mebendazole. Four hours after administration, the percentage of mebendazole had declined to 1%. Absorption in humans was increased when the same dose was given with a meal.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • WSAVA List of Essential Medicines for Cats and Dogs
    The World Small Animal Veterinary Association (WSAVA) List of Essential Medicines for Cats and Dogs Version 1; January 20th, 2020 Members of the WSAVA Therapeutic Guidelines Group (TGG) Steagall PV, Pelligand L, Page SW, Bourgeois M, Weese S, Manigot G, Dublin D, Ferreira JP, Guardabassi L © 2020 WSAVA All Rights Reserved Contents Background ................................................................................................................................... 2 Definition ...................................................................................................................................... 2 Using the List of Essential Medicines ............................................................................................ 2 Criteria for selection of essential medicines ................................................................................. 3 Anaesthetic, analgesic, sedative and emergency drugs ............................................................... 4 Antimicrobial drugs ....................................................................................................................... 7 Antibacterial and antiprotozoal drugs ....................................................................................... 7 Systemic administration ........................................................................................................ 7 Topical administration ........................................................................................................... 9 Antifungal drugs .....................................................................................................................
    [Show full text]
  • WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/148799 Al 1 November 2012 (01.11.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 9/107 (2006.01) A61K 9/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A 61 47/10 (2006.0V) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US2012/034361 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 20 April 2012 (20.04.2012) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/480,259 28 April 201 1 (28.04.201 1) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant (for all designated States except US): BOARD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, OF REGENTS, THE UNIVERSITY OF TEXAS SYS¬ TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, TEM [US/US]; 201 West 7th St., Austin, TX 78701 (US).
    [Show full text]
  • Albendazole: a Review of Anthelmintic Efficacy and Safety in Humans
    S113 Albendazole: a review of anthelmintic efficacy and safety in humans J.HORTON* Therapeutics (Tropical Medicine), SmithKline Beecham International, Brentford, Middlesex, United Kingdom TW8 9BD This comprehensive review briefly describes the history and pharmacology of albendazole as an anthelminthic drug and presents detailed summaries of the efficacy and safety of albendazole’s use as an anthelminthic in humans. Cure rates and % egg reduction rates are presented from studies published through March 1998 both for the recommended single dose of 400 mg for hookworm (separately for Necator americanus and Ancylostoma duodenale when possible), Ascaris lumbricoides, Trichuris trichiura, and Enterobius vermicularis and, in separate tables, for doses other than a single dose of 400 mg. Overall cure rates are also presented separately for studies involving only children 2–15 years. Similar tables are also provided for the recommended dose of 400 mg per day for 3 days in Strongyloides stercoralis, Taenia spp. and Hymenolepis nana infections and separately for other dose regimens. The remarkable safety record involving more than several hundred million patient exposures over a 20 year period is also documented, both with data on adverse experiences occurring in clinical trials and with those in the published literature and\or spontaneously reported to the company. The incidence of side effects reported in the published literature is very low, with only gastrointestinal side effects occurring with an overall frequency of just "1%. Albendazole’s unique broad-spectrum activity is exemplified in the overall cure rates calculated from studies employing the recommended doses for hookworm (78% in 68 studies: 92% for A. duodenale in 23 studies and 75% for N.
    [Show full text]
  • Comparative Genomics of the Major Parasitic Worms
    Comparative genomics of the major parasitic worms International Helminth Genomes Consortium Supplementary Information Introduction ............................................................................................................................... 4 Contributions from Consortium members ..................................................................................... 5 Methods .................................................................................................................................... 6 1 Sample collection and preparation ................................................................................................................. 6 2.1 Data production, Wellcome Trust Sanger Institute (WTSI) ........................................................................ 12 DNA template preparation and sequencing................................................................................................. 12 Genome assembly ........................................................................................................................................ 13 Assembly QC ................................................................................................................................................. 14 Gene prediction ............................................................................................................................................ 15 Contamination screening ............................................................................................................................
    [Show full text]
  • I Comparative Activity of Anthelmintic
    Retour au menu Comparative activity of anthelmintic drugs, mebendazole, praziquantel and albendazole against Hymenolepis M. Gala1 ’ diminufa in experimentally infected S. R. Chin ’ Irats GALAL (MT), CHIN (S. R.). Comparaison de l’action de différents CAVIER and ROSSIGNOL (3) studied the taenicidal anthelminttuques (mébendazole, praziquantel et albendazole) contre properties of albendazole, mebendazole, niclosamide Hymenoleph diminuta chez des rats expérimentalement Infectés. Rev. Elev. Méd. vét. Pays trop., 1987, 40 (2) : 147-150. and praziquantel in experimentally infected mice and found that praziquantel and niclosamide have similar Des rats expérimentalement infectés avec If. diminufa ont été traités par voie orale avec trois anthelminthiques, administrés soit en dose taenicidal propet-ties. unique, soit en tiers de dose 3 jours consécutifs. Le praziquantel (250 mgkg ou 83 mg/k&j 3 fois) et I’alhendazole (800 mgkg ou Now are reported the comparative efficacy of meben- 167 mgkg/j 3 fois) ont totalement éliminé les vers, alors que le dazole, praziquantel and albendazole against experi- mébendazole (500 rng/kg- - ou 167 mg/kg/i- -. 3 fois) ne les a aue oartielle- mental infection of rats with H. diminuta, using single ment éliminés, avec une efficacité de 76 p. 160. Parmi ces j anthel- and divided oral doses for 3 consecutive days, 30 days mlnthlques, il n’a pas été relevé de différence signiiïcative d’efkacité entre les différents dosages pour chaque traitement. Aucune toxicité after infection. n’est apparue chez les rats traités. Mots CES : Rat - Helminthosc - Hymenolepis diminuta - Anthelminthique - Mébendazole - Prazi- quantel - Albendazole - Infection expérimentale. MATERIALS AND METHODS INTRODUCTION Definitive and intermediate hosts Albino rats (Rattus norvegicus) of both sexes and H.
    [Show full text]
  • Drug-N-Therapeutics-Committee.Pdf
    Irrational use of medicines is a widespread problem at all levels of health care, but especially GUIDE DRUG AND THERAPEUTICS COMMITTEES: A PRATICAL in hospitals. This is particularly worrying as resources are generally scarce and prescribers in communities often copy hospital prescribing practices. Use of medicines can be greatly improved and wastage reduced if some simple principles of drug management are followed. But it is difficult to implement these principles because staff from many different disciplines are involved, often with no forum for bringing them together to develop and implement appropriate medicines policies. A drug and therapeutics committee (DTC) provides such a forum, allowing all the relevant people to work together to improve health care delivery, whether in hospitals or other health facilities. In many developed countries a well functioning DTC has been shown to be very effective in addressing drug use problems. However, in many developing countries DTCs do not exist and in others they do not function optimally, often due to lack of local expertise or a lack of incentives. Drug and Therapeutics Committees: A Practical Guide provides guidance to doctors, pharmacists, hospital managers and other professionals who may be serving on DTCs and/or who are concerned with how to improve the quality and cost efficiency of therapeutic care. It is relevant for all kinds of DTCs - whether in public or private hospitals and whether at district or tertiary referral level. This comprehensive manual covers a committee’s functions and structure, the medicines formulary process, and how to assess new medicines. The chapters on tools to investigate drug use and strategies to promote rational use are followed by a discussion of antimicrobial resistance and infection control.
    [Show full text]
  • Anthelmintics Are Drugs Used to Treat Parasitic Infections Due to Worms
    “ANTHEMINTICS" Presented By Mr.Ghule A.V. Assistant Professor, MES’S,College Of Pharmacy,Sonai. INTRODUCTION Helminth means worms. Helminthiasis is an infections caused by parasitic worms. Anthelmintics are drugs used to treat parasitic infections due to worms. Anthelmintics act through two mechanism . Vermicide (kill) used to kill parasitic intestinal worms. Vermifuge (expel) used to destroy or expel worms in the intestine. Helminths are 3 types Nematodes (round worms) - ascarids (Ascaris), filarias, hookworms, pinworms (Enterobius), and whipworms (Trichuris trichiura) Cestodes (tape worms) - multiple species of flat worms, Taenia saginatum, Taenia solium(cysticercosis, hydatid(echinococcus), Trematodes (flukes) – liver flukes, lung flukes, schistosoma BASED ON CHEMICAL STRUCTURES Benzimidazoles : Albendazole , Mebendazole ,Flubendazole, Cyclobendazole Thiabendazole, Fenbendazole, Oxibendazole, Parbendazole Quinolines and isoquinolines [Heterocyclics]: Oxamniquine, Praziquantel Piperazine derivatives: Piperazine citrate, Diethyl carbamazine Vinyl pyrimidines: Pyrantel pamoate, Oxantel Amides : Niclosamide Natural products: Ivermectin Organo phosphorus: Metrifonate Imidazothiazoles: Levamisole Nitro derivatives: Niridazol BENZIMIDAZOLES Benzimidazole is a heterocyclic aromatic organic compound. This bicyclic compound consists of the fusion of benzene and imidazole. Many anthelmintic drugs(albendazole, mebendazole, etc.) belong to the benzimidazole class of compounds. ALBENDAZOLE It selectively bind to nematode ß-tubulin
    [Show full text]
  • World Health Organization Model List of Essential Medicines, 21St List, 2019
    World Health Organizatio n Model List of Essential Medicines 21st List 2019 World Health Organizatio n Model List of Essential Medicines 21st List 2019 WHO/MVP/EMP/IAU/2019.06 © World Health Organization 2019 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. World Health Organization Model List of Essential Medicines, 21st List, 2019. Geneva: World Health Organization; 2019. Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data. CIP data are available at http://apps.who.int/iris.
    [Show full text]